|
US2020383946A1
|
|
Lipoic acid formulations
|
|
US2020085618A1
|
|
Intrascleral drug delivery device and associated methods
|
|
WO2019071275A1
|
|
Non-invasive ocular drug delivery devices
|
|
US2019216830A1
|
|
Ophthalmic compositions
|
|
US2019105194A1
|
|
Methods of treating a subject with an ocular condition responsive to steroid therapy
|
|
US2019105264A1
|
|
Non-invasive ocular drug delivery devices
|
|
WO2008013913A2
|
|
Method and device for minimally invasive site specific ocular drug delivery
|
|
WO2007050645A2
|
|
Intraocular iontophoretic device and associated methods
|
|
US2007082841A1
|
|
Ocular administration of immunosuppressive agents
|
|
CN101437570A
|
|
Methods and devices for sustained in-vivo release of an active agent
|
|
AU2005299601A1
|
|
Methods and devices for sustained in-vivo release of an active agent
|
|
WO2004077012A2
|
|
Methods and systems for controlling and/or increasing iontophoretic flux
|
|
US7785578B2
|
|
Non-invasive ocular drug delivery
|
|
WO03010538A1
|
|
Method and apparatus for increasing, flux during reverse iontophoresis
|
|
US6801804B2
|
|
Device and method for monitoring and controlling electrical resistance at a tissue site undergoing iontophoresis
|
|
US7137975B2
|
|
Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
|
|
US6553255B1
|
|
Use of background electrolytes to minimize flux variability during iontophoresis
|
